TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Delta4's Computational Hyper-C Drug Discovery Platform Uncovers Promising Therapeutic Option for Focal Segmental Glomerulosclerosis (FSGS)

Monday, June 19, 2023

Delta4, an innovative company specializing in digital drug discovery, has achieved a significant breakthrough in the search for new treatments for Focal Segmental Glomerulosclerosis (FSGS).

FSGS is a serious kidney condition characterized by glomerular damage and nephrotic syndrome, often leading to kidney disease progression. Unfortunately, the available therapeutic options for FSGS are limited, emphasizing the critical need for targeted therapies that address specific molecular pathways. Delta4's pioneering Computational Hyper-C Drug Discovery Platform has identified a potential therapeutic option that holds promise in addressing this unmet medical need.

Delta4, a company specializing in drug discovery, has made a significant advancement in the field of Focal Segmental Glomerulosclerosis (FSGS) research. Utilizing their state-of-the-art proprietary AI platform called Hyper-C and drawing on the expertise of their computational biologists, Delta4 has developed a network-based molecular model of FSGS pathophysiology. This innovative approach has enabled them to comprehensively evaluate compounds and their potential to interfere with the molecular processes involved in FSGS.

Through extensive computational screening, Delta4 has identified clopidogrel, an anti-platelet drug, as a promising candidate for FSGS treatment. In a mouse model of FSGS induced by Adriamycin, clopidogrel demonstrated notable potential in improving key outcome parameters and reducing histopathological damage.

Dr. Paul Perco, Delta4's Computational Biology Lead and the corresponding author of a recently published manuscript in Translational Research, expressed confidence in clopidogrel's therapeutic potential for FSGS. He stated that the drug's favorable safety profile, combined with its efficacy in the mouse model, positions it as a promising candidate for future clinical trials.

Kurt Herpel, the CEO of Delta4, emphasized the groundbreaking nature of their approach, which leverages AI and computational biology to rapidly identify safe and effective treatments for complex diseases like FSGS. Delta4 is committed to revolutionizing drug discovery and addressing the unmet medical needs of patients with rare diseases by harnessing their AI capabilities and deep scientific understanding.

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit